MyDrHank NAD+ Review: What the $137 Price Actually Buys

MyDrHank advertises NAD+ at $137 a month. The month-to-month price is $199, and $199 is printed on no page of its website. It sells a nasal spray and an injection.

Most NAD+ telehealth clinics will not tell you what they charge until you have handed over an email address and answered a quiz. MyDrHank does — its NAD+ page prints a figure before you fill in anything, and it sells both of the routes we rank providers on. On this site's own rubric, published pricing is the first thing we reward, so that ought to put it in good standing.

Then you read the figure carefully. This review is mostly about how $137 becomes $199, because the mechanism is not a typo and it is not unique to this company; it is just unusually easy to demonstrate here.

What MyDrHank is

MyDrHank is a prescription telehealth practice operated by Dr. Hank, LLC — an entity the site credits by name in both its privacy policy and its terms of use, which is more than several of the clinics on our ranked NAD+ provider ranking manage. A U.S.-licensed clinician reviews an online intake and, if you qualify, a state-licensed U.S. compounding pharmacy fills the prescription. The pharmacy itself is not named.

NAD+ is one shelf of six. The catalog runs weight loss, longevity, peptides and NAD+, sexual health, hair growth and strength, and the company describes its GLP-1 line as the popular one. That matters for expectation-setting: this is a broad prescription platform with a NAD+ product on it, not a NAD+ specialist. The NAD+ line comes two ways — a nasal spray and a subcutaneous injection — which is the same pair our #1 pick sells, and the reason MyDrHank is here at all rather than filed as an off-category offer.

The price: every figure on the site is a year paid up front

Here is the full ladder, quoted from the product records in MyDrHank's own front-end bundle.

The nasal spray is $199 for one month. Three months is $507, which the record calls $169 a month. Six months is $913, or $152 a month. Twelve months is $1,644, or $137 a month. The injection runs the same shape one rung higher: $225 monthly, $574 a quarter ($191/mo), $1,033 for six months ($172/mo), $1,859 for a year ($155/mo).

Now the mechanism. The component that prints a price on a MyDrHank product page does not choose a rung — it takes the minimum of the per-month figures across the whole ladder and renders it as "From $X /mo". There is only one possible output of that function: the twelve-month rung. So every price MyDrHank displays anywhere on its site is, by construction, the annual prepay rate. The $199 and the $225 exist in the data and are never shown to anyone.

This is checkable rather than inferred. The ladder's plan names and totals — "Monthly", "Quarterly", "$1,644" — are all present in the bundle's product data, and the field holding them is referenced in zero rendering expressions. The rungs are not hidden behind a tab or a toggle. They are not on the site.

The sharpest version of the problem is one line on the landing page our readers arrive at, which reads: "Starting at $137/month · Cancel anytime." Both halves are true of MyDrHank in general and neither is true of the same purchase. If you are paying $137 a month you have already paid $1,644 for a year; if you can genuinely cancel at any time, you are on the $199 plan. There is no product for which that sentence describes your position.

To be fair about where the trap sits: the same landing page states plainly that "final pricing depends on the protocol and dose prescribed," so the company is not claiming the number is fixed. It is the reference point that is wrong, not the caveat. And this is worth saying precisely, because MyDrHank's GLP-1 pages carry a promise its NAD+ pages do not — "the price stays the same at every dose — no surprise price increases" appears only in the weight-loss FAQ. Do not carry it across. The NAD+ line says the opposite.

One more thing that fell out of reading the bundle, on the weight-loss side rather than this one: a footnote advertises "$200/mo for compounded tirzepatide." No tirzepatide plan costs $200 at any rung — the ladder is $349, $297, $267 and $240. The $171 in that same sentence is the oral product's annual rate; the injectable's is $178. That is the same display habit producing a figure that is not merely optimistic but unavailable.

The evidence problem: a citation for a different molecule

The NAD+ pages lead with a statistic: "6x increase in whole blood NAD+ after 12 weeks of supplementation." It is footnoted, which is rarer in this category than it should be, and the footnote names a real trial: Igarashi and colleagues, npj Aging, 2022 — a randomized, double-blind, placebo-controlled study¹. Both the nasal spray and the injection carry that same citation.

We read the paper. Three things do not survive the trip.

It is not this molecule, and not this route. Igarashi 2022 gave 250 mg a day of oral nicotinamide mononucleotide — NMN, a precursor your body converts — to men aged 65 and over. MyDrHank sells NAD+ itself, sprayed into the nose or injected under the skin. A precursor swallowed as a capsule and a compound sprayed into a nostril are not interchangeable evidence, and the whole marketing case for the nasal route is that it behaves differently from something swallowed. The citation therefore argues against the product's own positioning.

The 6x is not in the paper. The trial reports that NMN significantly raised blood NAD+ and its metabolites. It reports no fold-change at all — there is no six-fold figure, and no n-fold figure of any size, anywhere in the full open-access text.

Nobody measured thinking. The functional outcomes were gait speed and grip strength, and the authors describe the improvements they saw as nominally significant and in need of validation in larger studies. No cognitive endpoint was assessed. Which means a statistic being used to sell "mental clarity" and "focus" comes from a trial that did not measure either.

It is also a small and messy trial, and worth knowing on its own terms: 42 men were randomized and 20 finished, three of the authors were employees of an NMN manufacturer, and — disclosed in the paper itself — a supplier error meant 11 participants in each arm were handed the other group's supplement at the six-week visit.

None of this is a MyDrHank-specific failing so much as a category-wide one, which is why we grade every provider on this site's rankings against the same line: no rigorous human trial shows that nasal, injected or intravenous NAD+ improves cognition or energy. The closest real results run the other way. In older adults with mild cognitive impairment, oral nicotinamide riboside raised NAD+ and did not improve cognition against placebo²; a second randomized trial in people with subjective cognitive decline and MCI likewise found no cognitive benefit³. The only human data on a parenteral route is a pilot that tracked NAD+ metabolites through a six-hour infusion and measured no cognitive outcome whatsoever⁴. We go through all of it in our NAD+ brain fog and focus evidence review, and the precursor literature specifically in what the NMN and NR trials actually found.

What it gets right

Two things, and they are not small.

The first is its own safety block, which is franker than most of this field manages. It states in writing that compounded drugs are not FDA-approved and have not been evaluated by the FDA for safety, efficacy or quality — and then goes further than it had to: "Clinical evidence for nasal and injectable NAD+ delivery is limited and based largely on preclinical and observational research." A company selling nasal NAD+ writing that down is genuinely unusual, and it sits oddly beside the 6x headline three screens above it.

The second is regulatory. No FDA warning letter names the MyDrHank brand, its operating entity or its domain (checked August 2026). That is not a trivial pass in this category: three companies on our own NAD+ ranking carry live warning letters, and we disclose each one where we rank it. MyDrHank is clean.

What it will not tell you

Where it operates. "NAD+ is available in select U.S. states" is the whole disclosure. No list appears anywhere on the consumer site, so the only way to discover you are in the wrong state is to complete an intake.

Which pharmacy. "A state-licensed U.S. compounding pharmacy" on the lander, "accredited U.S. pharmacies" on the product page. Neither names a facility, so there is nothing to look up.

How often you inject. The landing page describes the line as "a daily nasal spray or weekly injection." The product page's own FAQ says to inject "subcutaneously 2–3 times per week." Those are different products in terms of both routine and, plausibly, cost per dose, and a reader cannot tell from the outside which is right.

Who it is for, and who it is not

If you have already decided you want prescription NAD+, you want the nasal route or the needle, and you are willing to commit to a year, MyDrHank's $137 is a real number and among the lower ones we have verified for a clinician-supervised program. Pay it with your eyes open: it is $1,644 today, not $137 this month.

If you want a monthly commitment, the honest comparison is $199 against the flat rates on our ranking of NAD+ providers ranked on published price, where the top of the list charges the same figure whichever route you pick and does not need you to prepay a year to reach it. And if you are shopping the needle specifically, the NAD+ injection comparison puts MyDrHank's $225 beside every other injectable we could price.

If you are here because your head feels foggy and you are hoping a prescription will lift it, please read what actually causes brain fog before spending anything. Sleep, thyroid, iron, B12, medication and alcohol account for far more foggy thinking than a coenzyme deficiency does, and none of them costs $1,644.

The bottom line

MyDrHank is a legitimate, FDA-clean prescription telehealth practice selling both NAD+ routes with a named operating entity and an unusually candid evidence disclaimer — and it advertises a price that only exists if you pay for a year in advance, beside the words "cancel anytime," under a statistic borrowed from a trial of a different molecule taken a different way that measured no cognitive outcome at all. On price transparency it ranks below every provider in our ranking that publishes a rate you can actually be charged month to month, and above the three that publish no rate at all. That is where we have put it.